CNBC Investing Club

Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken

David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC

Eli Lilly's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. While the setback hit the stock Friday, it's not rattling our long-term belief in the company.